

10/509675

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DT04 Rec'd PCT/PTO 0 8 OCT 2004

In re the Application of:

Group Art Unit: Unknown

Piero DEL SOLDATO

Examiner: Unknown

Application No.: New Application

Atty. Dkt. No.: 026220-00055

Filed: October 8, 2004

For: DRUGS FOR THE ARTHRITIS TREATMENT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

October 8, 2004


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,



Richard U. Berman
Registration No. 39,107

Customer No. 004372
Arent Fox PLLC
1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

RJB:mso

Enclosures: PTO-1449 Form; Search Report; References (13)

FORM PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 026220-00055	SERIAL NO. 101509675
	APPLICANT Piero DEL SOLDATO			
	FILING DATE October 8, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
/J.L./	AA	5,621,000	4/15/1997	Barbara ARENA, et al.			
/J.L./	AB	5,861,426	1/19/1999	Piero DEL SOLDATO, et al.			
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
							YES	NO	PART.
/J.L./	AG	DE 44 20 523 A1	12/14/1995	Deutschland				XX	
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	AM	Piero DEL SOLDATO, et al.; "No-Aspirins: A Class of New Anti-Inflammatory and Antithrombotic Agents"; August 1999; Vol. 20, No. 8 Pages 319-323
/J.L./	AN	L. CUZZOLIN, et al.; "Anti-Inflammatory Potency and Gastrointestinal Toxicity of A New Compound, Nitronaproxen"; August 26, 1994; Vol. 31, No. 1, Pages 61-65
/J.L./	AO	P. DEL SOLDATO, et al.; "Nitric-Oxide-Releasing NSAIDs, A Novel Class of Safe and Effective Anti-Inflammatory Agents; 1996; Vol. 4, No. 2, Pages 181-188

EXAMINER /Jonathan Lau/	DATE CONSIDERED 05/08/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 104509675 New Application
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO	
		FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	AM	Shinichi KATO, et al.; "Low Gastric Toxicity of Nitric Oxide-Releasing Aspirin, NCX-4016, in Rats with Cirrhosis and Arthritis"; August 2001; Vol. 46, No.8, Pages 1690-1699
/J.L./	AN	Stefano FIORUCCI, et al.; "No-Releasing NSAIDs Modulate Cytokine Secretion"; 2001; Vol. 16, Pages 171-178
/J.L./	AO	R J VAN'T HOF; "No-NSAIDs: A Novel Class of Osteoclast Inhibitors; May 7, 1999; Vol. 64 No. SUPPL 1, Page S59

EXAMINER /Jonathan Law/	DATE CONSIDERED 05/08/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 104508475 New Application
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO	
		FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
							YES	NO	PART.
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	AM	J.L. BURGAUD, et al.; "Treatment of Septic Shock Treatment of Urinary Incontinence Treatment of Osteoporosis Nitric Oxide Donor"; 1999; Vol. 24, No. 8, Pages 858-861
/J.L./	AN	Kenneth J. ARMOUR, et al.; "Inhibition of Bone Resorption In Vitro and Prevention of Ovariectomy-Induced Bone Loss In Vivo by Flurbiprofen Nitroxybutylester (HCT1026); September 2001; Vol. 44, No. 9, Pages 2185-2192
/J.L./	AO	Mark J. PAUL-CLARK, et al. "Potent Antiarthritic Properties of a Glucocorticoid derivative, NCX-1015, in an Experimental Model of Arthritis"; February 5, 2002; Vol. 99, No. 3, Pages 1677-1682

EXAMINER /Jonathan Lau/	DATE CONSIDERED 05/08/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 4 of 4

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 107509675 New Application
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO	
		FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART.		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)

/J.L./	AM	J.L. BURGAUD, et al. "Nitric-Oxide Releasing Molecules: A New Class of Drugs with Several Major Indications"; 2002; Vol. 8, No. 3, Pages 201-213
	AN	
	AO	

EXAMINER /Jonathan Lau/	DATE CONSIDERED 05/08/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	